Katherine Ruzhansky, MD
Neurology · Charleston, SCNPI 1558526947
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,583 of the $51,949 with a category attached, or 82.0%. 11 manufacturers reported payments, led by AstraZeneca at 45.1% of the total. Reporting peaked in 2019 at $12,946 and has fallen 82.9% since, to $2,211 in 2025. Among neurology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $552.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$23K
- UCB, Inc.$10K
- Alnylam Pharmaceuticals Inc.$6K
- Johnson & Johnson$6K
- Argenx US, Inc.$4K
- Akcea Therapeutics, Inc.$2K
- plus $972 from 5 others
Across 99 payments — averaging $11,019 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$374K
- AstraZeneca$370K
- UCB SA$294K
- Alnylam Pharmaceuticals Inc.$37K
- Argenx US, Inc.$14K
- UCB Biosciences Inc.$1K
What the payments were for
- Consulting fees$42,58382%
- Speaking & faculty fees$2,8806%
- Travel & lodging$2,9056%
- Food & beverage$3,5817%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $23,436 |
| UCB, Inc. | 14 | $9,789 |
| Alnylam Pharmaceuticals Inc. | 27 | $6,118 |
| Johnson & Johnson | 7 | $5,654 |
| Argenx US, Inc. | 7 | $4,120 |
| Akcea Therapeutics, Inc. | 2 | $1,860 |
| Amgen | 1 | $550 |
| Vertex | 1 | $225 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Natus Medical Incorporated | 1 | $53 |
| Tanabe Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,949 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZilbrysqZilucoplan Sodium | 15 | $641,040 |
| Radicava OrsEdaravone | 31 | $435,446 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $234,735 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 28 | $134,264 |
| EmflazaDeflazacort | 12 | $65,660 |
| Mycophenolate Mofetil | 65 | $6,754 |
| Riluzole | 41 | $4,708 |
| Pyridostigmine Bromide | 65 | $4,249 |
| Azathioprine | 32 | $1,524 |
| Prednisone | 65 | $385 |
| Levetiracetam | 12 | $288 |
| Gabapentin | 11 | $279 |
| Baclofen | 14 | $207 |
| Sodium ChlorideSodium Chloride 0.45 % | 17 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Zilbrysq | $9,789 | $641,04015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.
Other neurology in Charleston
- Robert AdamsCharleston$204K
- Sarah BreevoortCharleston$90K
- Tanya TuranCharleston$77K
- Jonathan HalfordCharleston$48K
- Andrew KeeganCharleston$48K
- Aljoeson WalkerCharleston$35K
- Hamid BahadoriCharleston$29K
- Bruce OvbiageleCharleston$27K
- Andrew AmeriCharleston$24K
- Robert BolenCharleston$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.